FDA grants Priority Review to DATROWAY (datopotamab deruxtecan-dlnk) in the U.S. for advanced triple negative breast cancer. EU CHMP issues a positive opinion for Imfinzi (durvalumab) plus ...

The FDA has accepted and granted Priority Review for DATROWAY, co-developed by AstraZeneca (LSE:AZN) and Daiichi Sankyo, as a first-line treatment for certain patients with metastatic triple-negative ...

AstraZeneca and Daiichi Sankyo have received U.S. FDA Priority Review for DATROWAY for metastatic triple negative breast ...

AstraZeneca’s cancer drug DATROWAY has received U.S. FDA Priority Review for use in advanced breast cancer. The company has expanded its collaboration with CSPC Pharmaceuticals in obesity and diabetes ...

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression and a ...

Sanofi announced the signing of a share buyback mandate for up to €1 billion. Pfizer said its obesity injection, which was ...

AstraZeneca named a new CFO, and its current CFO will become its chief strategy officer and the CEO of Alexion, the drugmaker announced June 4. In December 2020, AstraZeneca said it was acquiring ...

Achilles Therapeutics plc has announced the transfer of data and samples from its TRACERx Non-Small Cell Lung Cancer study and its Material Acquisition Platform (MAP) to AstraZeneca for a total ...